Participated · Series B · Jun 2026

Attention builds an AI platform whose agents act inside revenue workflows to draft and send follow-ups, update systems of record, and execute next plays rather than just summarizing interactions. The company is developing an autonomous action engine that surfaces and executes reps’ highest‑impact next moves, then learns from outcomes to improve over time. Attention reports it is running over 20 million agent actions per month and that annual recurring revenue has grown 4x year-over-year, while average contract value has expanded 10x over two years. It serves more than 500 customers, including Abridge, Scale, Lovable, Preply, Engine, and BambooHR. Customers have credited measurable outcomes to the platform, such as Abridge’s 5x coaching efficiency and 4x sales growth, Unify’s 40% win-rate improvement, and Certificial’s reduction in forecasting margin of error from 15% to 5%. Attention was founded in 2021 and is headquartered in New York.

Led · Series A · Apr 2026

Generare builds a platform combining high-throughput cloning and sequencing to identify, express, and characterise novel small molecules from microbial genomes, generating structured data on their properties. The company is focused on expanding the accessible chemical space for drug discovery by creating a large-scale dataset of previously unexplored molecular diversity. Founded in 2023, Generare reports growing adoption of its platform among pharmaceutical and research organisations, with discovered molecules entering early-stage drug development. Its immediate plans include expanding its compound library, scaling its discovery capabilities, and hiring across a multidisciplinary team to meet demand. Financially, the company recently secured €20 million in a Series A to fund those growth initiatives.

Participated · Series A · Mar 2026

Kestra Technologies builds Kestra, an open-source orchestration control plane designed to unify data pipelines, AI workflows, infrastructure automation and business processes across hybrid and air-gapped environments. Founded in 2021 by Emmanuel Darras and Ludovic Dehon, the platform is used by more than 30,000 organizations and recorded over 2 billion workflow executions in 2025, while earning 26,000+ GitHub stars. Since its seed round 18 months ago the company says enterprise revenue grew 25× and adoption expanded at large enterprises including Apple, Toyota, JPMorgan Chase, BHP and Crédit Agricole. Kestra offers a plugin ecosystem (1,200+ plugins) and emphasizes declarative, extensible orchestration for mission-critical use cases. The company plans to ship Kestra 2.0—a distributed execution engine with real-time observability and native agentic orchestration—and launch Kestra Cloud, a fully managed SaaS with usage-based pricing, while expanding go-to-market and open-source investments.

Participated · Series B · Mar 2026

Cryptio offers a platform that standardizes and reconciles fragmented on-chain and off-chain data from blockchains, exchanges, custodians and brokerages to produce audit-ready financial records for regulated digital-asset activity. Its ERP-grade applications support accounting, reporting and operational workflows and are designed to meet institutional control and audit standards used by firms including Deloitte, EY, KPMG and PwC. Cryptio has expanded beyond accounting into Loan Management and Treasury Management applications to address institutional lending and treasury workflows. The company supports over 400 enterprises in more than 30 countries, has processed over $3 trillion in transaction volume, and counts customers such as Circle, Société Générale (SG Forge), Gemini and Securitize. Cryptio positions itself as core infrastructure for regulated digital-asset markets, enabling reconciliation of token supply and lifecycle activity including minting and burning.

Led · Series A · Feb 2026

Verley engineers beta-lactoglobulin (BLG) whey proteins through precision fermentation, selling them under the FermWhey™ range to manufacturers looking for high-protein, clean-label and easily digestible ingredients. The proteins are functionalized to improve solubility, emulsification, gelling and nutritional profiles, enabling applications such as high-protein yoghurts and protein shots. By using fermentation rather than conventional dairy production, Verley claims to cut natural-resource consumption and help alleviate structural supply constraints in traditional whey. In less than four years, the company has secured self-affirmed GRAS status (2024) and an FDA “No Questions” letter (2025), validating product safety for the U.S. market. Verley holds a growing IP portfolio around both fermentation and protein functionalisation technologies that aim to outperform standard dairy proteins. The fresh capital will fund U.S. commercial rollout, early customer scale-up and increased production capacity, followed by planned expansion in Europe and the Middle East. Continued R&D investment is earmarked to push performance, efficiency and sustainability of its platform.